Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study
<i>Background and Objectives: </i>This article presents data from the ongoing Aiginition Longitudinal Biomarker Investigation of Neurodegeneration study (ALBION) regarding baseline clinical characterizations and CSF biomarker profiles, as well as preliminary longitudinal data on clinical...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/9/1179 |
| _version_ | 1797485112031444992 |
|---|---|
| author | Nikolaos Scarmeas Argyro Daskalaki Faidra Kalligerou Eva Ntanasi Eirini Mamalaki Antonios N. Gargalionis Kostas Patas Stylianos Chatzipanagiotou Mary Yannakoulia Vasilios C. Constantinides |
| author_facet | Nikolaos Scarmeas Argyro Daskalaki Faidra Kalligerou Eva Ntanasi Eirini Mamalaki Antonios N. Gargalionis Kostas Patas Stylianos Chatzipanagiotou Mary Yannakoulia Vasilios C. Constantinides |
| author_sort | Nikolaos Scarmeas |
| collection | DOAJ |
| description | <i>Background and Objectives: </i>This article presents data from the ongoing Aiginition Longitudinal Biomarker Investigation of Neurodegeneration study (ALBION) regarding baseline clinical characterizations and CSF biomarker profiles, as well as preliminary longitudinal data on clinical progression. <i>Materials and Methods: </i>As of March 2022, 138 participants who either were cognitively normal (CN, <i>n</i> = 99) or had a diagnosis of mild cognitive impairment (MCI, <i>n</i> = 39) had been recruited at the specialist cognitive disorders outpatient clinic at Aiginition Hospital. Clinical characteristics at baseline were provided. These patients were followed annually to determine progression from CN to MCI or even dementia. CSF biomarker data (amyloid β1-42, phosphorylated tau at threonine 181, and total tau) collected using automated <i>Elecsys</i><sup>®</sup> assays (<i>Roche</i> Diagnostics) were available for 74 patients. These patients were further sorted based on the AT(N) classification model, as determined by CSF Aβ42 (A), CSF pTau (T), and CSF tTau (N). <i>Results:</i> Of the 49 CN patients with CSF biomarker data, 21 (43%) were classified as exhibiting “Alzheimer’s pathologic change” (A+Τ– (Ν)−) and 6 (12%) as having “Alzheimer’s disease” (A+T–(N)+, A+T+(N)–, or A+T+(N)+). Of the 25 MCI patients, 8 (32%) displayed “Alzheimer’s pathologic change”, and 6 (24%) had “Alzheimer’s disease”. A total of 66 individuals had a mean follow-up of 2.1 years (SD = 0.9, min = 0.8, max = 3.9), and 15 of those individuals (22%) showed a clinical progression (defined as a worsening clinical classification, i.e., from CN to MCI or dementia or from MCI to dementia). Overall, participants with the “AD continuum” AT(N) biomarker profile (i.e., A+T–(N)–, A+T–(N)+, A+T+(N)–, and A+T+(N)+) were more likely to clinically progress (<i>p </i>= 0.04). <i>Conclusions: </i>A CSF “AD continuum” AT(N) biomarker profile is associated with an increased risk of future clinical decline in CN or MCI subjects. |
| first_indexed | 2024-03-09T23:15:07Z |
| format | Article |
| id | doaj.art-d4460309e6fc4da0bb6275a54ddc6334 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T23:15:07Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-d4460309e6fc4da0bb6275a54ddc63342023-11-23T17:39:06ZengMDPI AGMedicina1010-660X1648-91442022-08-01589117910.3390/medicina58091179Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) StudyNikolaos Scarmeas0Argyro Daskalaki1Faidra Kalligerou2Eva Ntanasi3Eirini Mamalaki4Antonios N. Gargalionis5Kostas Patas6Stylianos Chatzipanagiotou7Mary Yannakoulia8Vasilios C. Constantinides91st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, 11528 Athens, Greece1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, 11528 Athens, Greece1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, 11528 Athens, Greece1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, 11528 Athens, GreeceDepartment of Nutrition and Diatetics, Harokopio University, 17671 Athens, GreeceDepartment of Medical Biopathology, Aiginition Hospital, 11528 Athens, GreeceDepartment of Medical Biopathology, Aiginition Hospital, 11528 Athens, GreeceDepartment of Medical Biopathology, Aiginition Hospital, 11528 Athens, GreeceDepartment of Nutrition and Diatetics, Harokopio University, 17671 Athens, Greece1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, 11528 Athens, Greece<i>Background and Objectives: </i>This article presents data from the ongoing Aiginition Longitudinal Biomarker Investigation of Neurodegeneration study (ALBION) regarding baseline clinical characterizations and CSF biomarker profiles, as well as preliminary longitudinal data on clinical progression. <i>Materials and Methods: </i>As of March 2022, 138 participants who either were cognitively normal (CN, <i>n</i> = 99) or had a diagnosis of mild cognitive impairment (MCI, <i>n</i> = 39) had been recruited at the specialist cognitive disorders outpatient clinic at Aiginition Hospital. Clinical characteristics at baseline were provided. These patients were followed annually to determine progression from CN to MCI or even dementia. CSF biomarker data (amyloid β1-42, phosphorylated tau at threonine 181, and total tau) collected using automated <i>Elecsys</i><sup>®</sup> assays (<i>Roche</i> Diagnostics) were available for 74 patients. These patients were further sorted based on the AT(N) classification model, as determined by CSF Aβ42 (A), CSF pTau (T), and CSF tTau (N). <i>Results:</i> Of the 49 CN patients with CSF biomarker data, 21 (43%) were classified as exhibiting “Alzheimer’s pathologic change” (A+Τ– (Ν)−) and 6 (12%) as having “Alzheimer’s disease” (A+T–(N)+, A+T+(N)–, or A+T+(N)+). Of the 25 MCI patients, 8 (32%) displayed “Alzheimer’s pathologic change”, and 6 (24%) had “Alzheimer’s disease”. A total of 66 individuals had a mean follow-up of 2.1 years (SD = 0.9, min = 0.8, max = 3.9), and 15 of those individuals (22%) showed a clinical progression (defined as a worsening clinical classification, i.e., from CN to MCI or dementia or from MCI to dementia). Overall, participants with the “AD continuum” AT(N) biomarker profile (i.e., A+T–(N)–, A+T–(N)+, A+T+(N)–, and A+T+(N)+) were more likely to clinically progress (<i>p </i>= 0.04). <i>Conclusions: </i>A CSF “AD continuum” AT(N) biomarker profile is associated with an increased risk of future clinical decline in CN or MCI subjects.https://www.mdpi.com/1648-9144/58/9/1179Alzheimer’s diseasebiomarkerCSF biomarkerneurodegenerationALBION study |
| spellingShingle | Nikolaos Scarmeas Argyro Daskalaki Faidra Kalligerou Eva Ntanasi Eirini Mamalaki Antonios N. Gargalionis Kostas Patas Stylianos Chatzipanagiotou Mary Yannakoulia Vasilios C. Constantinides Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study Medicina Alzheimer’s disease biomarker CSF biomarker neurodegeneration ALBION study |
| title | Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study |
| title_full | Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study |
| title_fullStr | Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study |
| title_full_unstemmed | Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study |
| title_short | Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study |
| title_sort | initial data and a clinical diagnosis transition for the aiginition longitudinal biomarker investigation of neurodegeneration albion study |
| topic | Alzheimer’s disease biomarker CSF biomarker neurodegeneration ALBION study |
| url | https://www.mdpi.com/1648-9144/58/9/1179 |
| work_keys_str_mv | AT nikolaosscarmeas initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT argyrodaskalaki initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT faidrakalligerou initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT evantanasi initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT eirinimamalaki initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT antoniosngargalionis initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT kostaspatas initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT stylianoschatzipanagiotou initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT maryyannakoulia initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy AT vasilioscconstantinides initialdataandaclinicaldiagnosistransitionfortheaiginitionlongitudinalbiomarkerinvestigationofneurodegenerationalbionstudy |